TY - JOUR
T1 - International Survey on Vein of Marshall Retrograde Ethanol Infusion
AU - De Becker, Benjamin
AU - Derval, Nicolas
AU - Amin, Reshma
AU - El Haddad, Milad
AU - Pambrun, Thomas
AU - Bouyer, Benjamin
AU - Francois, Clara
AU - De Smet, Maarten
AU - Channan, El Mehdi
AU - Blankoff, Nicolas
AU - Krahnefeld, Olaf
AU - Agdirlioglu, Tolga
AU - Minois, Damien
AU - Andorin, Antoine
AU - Bessiere, Francis
AU - Gardey, Kevin
AU - Sesselberg, Henry W.
AU - Leyton-Mange, Jordan S.
AU - Marchand, Hugo
AU - Mariottini, Claude
AU - Miled, Manel
AU - Sebag, Frédéric A.
AU - Lellouche, Nicolas
AU - Andronache, Marian
AU - Marchese, Procolo
AU - Rossi, Andrea
AU - Nesti, Martina
AU - Herzet, Jean Manuel
AU - Rodríguez Manero, Moisés
AU - Pavlović, Nikola
AU - Anselme, Frédéric
AU - Chaumont, Corentin
AU - Wijnmaalen, Adrianus P.
AU - Piers, Sebastiaan R.D.
AU - Waktare, Johan E.P.
AU - Najm, Ali
AU - Almorad, Alexandre
AU - Sousa, Pedro A.
AU - Lepièce, Caroline
AU - Badot, Damien
AU - Auquier, Nathanaël
AU - Efremidis, Michalis
AU - Lian, Evgeny
AU - Maslova, Vera
AU - Tavernier, René
AU - Duytschaever, Mattias
AU - Le Polain de Waroux, Jean Benoit
AU - Valderrabano, Miguel
AU - Knecht, Sébastien
N1 - Publisher Copyright:
© 2025
PY - 2025/12
Y1 - 2025/12
N2 - BACKGROUND: – Retrograde ethanolization of the vein of Marshall (VOM) has been identified as an adjunct technique in the treatment of persistent atrial fibrillation (AF) and left atrial tachycardia, as stated in the last consensus statement on ablation of AF. However, there is a lack of high-volume data on the technique. METHODS: – Through the collection of data from worldwide centers, we performed this international survey that aims to analyze the safety and procedural characteristics of VOM ethanolization in patients referred for treatment of AF or left atrial tachycardia. RESULTS: – We included 5579 patients (66 years; range, 20–93) from 26 centers, who underwent VOM ethanolization between 2008 and 2024 for persistent AF (81%), paroxysmal AF (9%), or left atrial tachycardia (10%) under deep sedation (53%) or general anesthesia (47%). A concomitant mitral isthmus line was attempted in 79% of the cases, achieving mitral isthmus block in 98% of patients. There were 0.92% of periprocedural serious adverse events, including 0.09% of peri-procedural death (5 patients). Three patients developed hemodynamic collapse immediately after VOM ethanolization, causing the death of 1 due to anaphylactic shock. One patient died following surgical drainage of pericardial effusion 3 weeks after the procedure. The 3 other deaths were not directly related to VOM ethanolization. Pericardial effusion was observed in 123 patients (2.2%) at the time of or immediately after the procedure, requiring drainage in 20 patients (0.36%) and later in 32 additional patients (0.57%), including 5 (0.09%) requiring drainage. Pacemaker implantation was required in 2 patients (0.04%), 1 for high-grade atrioventricular block and 1 for sinus node dysfunction. CONCLUSIONS: – This international survey shows that VOM ethanolization is predominantly performed in patients with persistent AF. It is associated with rare but potentially life-threatening adverse events. Mitral isthmus line ablation results in a very high rate of block when performed concomitantly.
AB - BACKGROUND: – Retrograde ethanolization of the vein of Marshall (VOM) has been identified as an adjunct technique in the treatment of persistent atrial fibrillation (AF) and left atrial tachycardia, as stated in the last consensus statement on ablation of AF. However, there is a lack of high-volume data on the technique. METHODS: – Through the collection of data from worldwide centers, we performed this international survey that aims to analyze the safety and procedural characteristics of VOM ethanolization in patients referred for treatment of AF or left atrial tachycardia. RESULTS: – We included 5579 patients (66 years; range, 20–93) from 26 centers, who underwent VOM ethanolization between 2008 and 2024 for persistent AF (81%), paroxysmal AF (9%), or left atrial tachycardia (10%) under deep sedation (53%) or general anesthesia (47%). A concomitant mitral isthmus line was attempted in 79% of the cases, achieving mitral isthmus block in 98% of patients. There were 0.92% of periprocedural serious adverse events, including 0.09% of peri-procedural death (5 patients). Three patients developed hemodynamic collapse immediately after VOM ethanolization, causing the death of 1 due to anaphylactic shock. One patient died following surgical drainage of pericardial effusion 3 weeks after the procedure. The 3 other deaths were not directly related to VOM ethanolization. Pericardial effusion was observed in 123 patients (2.2%) at the time of or immediately after the procedure, requiring drainage in 20 patients (0.36%) and later in 32 additional patients (0.57%), including 5 (0.09%) requiring drainage. Pacemaker implantation was required in 2 patients (0.04%), 1 for high-grade atrioventricular block and 1 for sinus node dysfunction. CONCLUSIONS: – This international survey shows that VOM ethanolization is predominantly performed in patients with persistent AF. It is associated with rare but potentially life-threatening adverse events. Mitral isthmus line ablation results in a very high rate of block when performed concomitantly.
KW - atrial fibrillation
KW - drainage
KW - ethanol
KW - hemodynamics
KW - tachycardia
UR - https://www.scopus.com/pages/publications/105025117435
UR - https://www.scopus.com/inward/citedby.url?scp=105025117435&partnerID=8YFLogxK
U2 - 10.1161/CIRCEP.125.014049
DO - 10.1161/CIRCEP.125.014049
M3 - Article
C2 - 41328577
AN - SCOPUS:105025117435
SN - 1941-3149
VL - 18
SP - e014049
JO - Circulation: Arrhythmia and Electrophysiology
JF - Circulation: Arrhythmia and Electrophysiology
IS - 12
ER -